Top

Published in:

01-08-2014 | NEXT GENERATION GENETIC COUNSELING

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

Authors: Heather Fecteau, Kristen J. Vogel, Kristen Hanson, Shannon Morrill-Cornelius

Published in: Journal of Genetic Counseling | Issue 4/2014

Abstract

Cancer genetics professionals face a new opportunity and challenge in adapting to the availability of cancer genetic testing panels, now available as a result of Next Generation Sequencing (NGS) technology. While cancer panels have been available for over a year, we believe that there is not yet enough data to create practice guidelines. Despite this, a year of experience allows us to provide our opinion on points to consider as cancer genetic counselors incorporate this testing technology into genetic counseling practice models. NGS technology offers the ability to potentially diagnose hereditary cancer syndromes more efficiently by testing many genes at once for a fraction of what it would cost to test each gene individually. However, there are limitations and additional risks to consider with these tests. Obtaining informed consent for concurrent testing of multiple genes requires that genetics professionals modify their discussions with patients regarding the potential cancer risks and the associated implications to medical management. We propose dividing the genes on each panel into categories that vary by degree of cancer risk (e.g. penetrance of the syndrome) and availability of management guidelines, with the aim to improve patient understanding of the range of information that can come from this testing. The increased risk for identifying variants of uncertain significance (VUS) when testing many genes at once must be discussed with patients. Pretest genetic counseling must also include the possibility to receive unexpected results as well as the potential to receive a result in the absence of related medical management guidelines. It is also important to consider whether a single gene test remains the best testing option for some patients. As panels expand, it is important that documentation reflects exactly which genes have been analyzed for each patient. While this technology holds the promise of more efficient diagnosis for many of our patients, it also comes with new challenges that we must recognize and address.

Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm, 8(8), 1308–1339. doi:https://doi.org/10.1016/j.hrthm.2011.05.020.PubMedCrossRef

ACMG Board of Directors. (2012). Points to consider in the clinical application of genomic sequencing. Genetics in Medicine, 14(8), 759–761. doi:https://doi.org/10.1038/gim.2012.74.CrossRef

Ambry Lab. (2013). Retrived from https://doi.org/www.ambrygen.com/sites/default/files/pdfs/ACMG%20shared%20slides.pdf.

Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G., Kelsey, A. M., Harris, M., et al. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20(34), 4621–4628. doi:https://doi.org/10.1038/sj.onc.1204621.PubMedCrossRef

Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71(6), 2222–2229. doi:https://doi.org/10.1158/0008-5472.can-10-3958.PubMedPubMedCentralCrossRef

Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:https://doi.org/10.1054/bjoc.2000.1167.PubMedPubMedCentralCrossRef

Domchek, S., & Weber, B. L. (2008). Genetic Variants of uncertain significance: flies in the ointment. Journal of Clinical Oncology, 26(1), 16–17. doi:https://doi.org/10.1200/JCO.2007.14.4154.PubMedCrossRef

Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology, 31(10), 1267–1270. doi:https://doi.org/10.1200/jco.2012.46.9403.PubMedCrossRef

Erkko, H., Xia, B., Nikkila, J., Schleutker, J., Syrjakoski, K., Mannermaa, A., et al. (2007). A recurrent mutation in PALB2 in Finnish cancer families. Nature, 446(7133), 316–319. doi:https://doi.org/10.1038/nature05609.PubMedCrossRef

Frank, B., Hemminki, K., Meindl, A., Wappenschmidt, B., Sutter, C., Kiechle, M., et al. (2007). BRIP1 (BACH1) variants and familial breast cancer risk: a case–control study. BMC Cancer, 7, 83. doi:https://doi.org/10.1186/1471-2407-7-83.PubMedPubMedCentralCrossRef

Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., et al. (2009). Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27(8), 1250–1256. doi:https://doi.org/10.1200/jco.2008.16.6959.PubMedCrossRef

Halbert, C. H., Stopfer, J. E., McDonald, J., Weathers, B., Collier, A., Troxel, A. B., et al. (2011). Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women’s concerns? Journal of Clinical Oncology, 29(32), 4302–4306. doi:https://doi.org/10.1200/jco.2010.33.1561.PubMedPubMedCentralCrossRef

Hamilton, J. G., Lobel, M., & Moyer, A. (2009). Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychology, 28(4), 510–518. doi:https://doi.org/10.1037/a0014778.PubMedPubMedCentralCrossRef

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” 2013, https://doi.org/www.nccn.org/index.asp.

Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., et al. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324(5924), 217. doi:https://doi.org/10.1126/science.1171202.PubMedPubMedCentralCrossRef

Kleihues, P., Schauble, B., Zur Hausen, A., Esteve, J., & Ohgaki, H. (1997). Tumors associated with p53 germline mutations: a synopsis of 91 families. The American Journal of Pathology, 150(1), 1–13.PubMedPubMedCentral

Lewis, A. G., Flanagan, J., Marsh, A., Pupo, G. M., Mann, G., Spurdle, A. B., et al. (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005–R1016. doi:https://doi.org/10.1186/bcr1336.PubMedPubMedCentralCrossRef

Li, F. P., Fraumeni, J. F., Jr., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., et al. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Research, 48(18), 5358–5362.PubMed

Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemistry Reviews, 32(4), 177–195.

Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F., Jr., & Li, F. P. (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10(2), 83–87.PubMed

Offit, K. (2011). Personalized medicine: new genomics, old lessons. Human Genetics, 130(1), 3–14. doi:https://doi.org/10.1007/s00439-011-1028-3.PubMedPubMedCentralCrossRef

Pletcher, B. A., Toriello, H. V., Noblin, S. J., Seaver, L. H., Driscool, D. A., Bennett, R. L., et al. (2007). Indications for genetic referral: a guide for health care professionals. Genetics in Medicine, 9(6), 385–389.PubMedPubMedCentralCrossRef

U.S. Preventive Services Task Force (2014). Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine 160 (4), I-16-16.

Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., et al. (2011). Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics, 43(11), 1104–1107. doi:https://doi.org/10.1038/ng.955.PubMedCrossRef

Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 39(2), 165–167. doi:https://doi.org/10.1038/ng1959.PubMedCrossRef

Rehm, H. L., Bale, S. J., Bayrak-Toydemir, P., Berg, J. S., Brown, K. K., Deignan, J. L., et al. (2013). ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine, 15(9), 733–747. doi:https://doi.org/10.1038/gim.2013.92.PubMedPubMedCentralCrossRef

Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.PubMedCrossRef

Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239–1241. doi:https://doi.org/10.1038/ng1902.PubMedCrossRef

Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., et al. (2011). Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. The Lancet Oncology, 12(6), 559–567. doi:https://doi.org/10.1016/s1470-2045(11)70119-x.PubMedCrossRef

Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037. doi:https://doi.org/10.1073/pnas.1115052108.PubMedPubMedCentralCrossRef

Title: The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing
Authors: Heather Fecteau
Kristen J. Vogel
Kristen Hanson
Shannon Morrill-Cornelius
Publication date: 01-08-2014
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 4/2014
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-014-9714-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Views of Genetics Health Professionals on the Return of Genomic Results

Incidental Findings from Clinical Genome-Wide Sequencing: A Review

Three Clinical Experiences with SNP Array Results Consistent with Parental Incest: A Narrative with Lessons Learned

Next Generation Genetic Counseling: Introduction to the Special Issue

Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology

A Qualitative Study of Healthcare Providers’ Perspectives on the Implications of Genome-Wide Testing in Pediatric Clinical Practice